Treatment of refractory/relapsed extranodal NK/T cell lymphoma with decitabine plus anti-PD-1: A case report

Lin-Jie Li, Jun-Yu Zhang

Specialty type: Hematology
Provenance and peer review: Unsolicited article; Externally peer reviewed.
Peer-review model: Single blind
Peer-review report’s scientific quality classification
Grade A (Excellent): A, A
Grade B (Very good): B, B
Grade C (Good): 0
Grade D (Fair): 0
Grade E (Poor): 0
P-Reviewer: Ekine-Afolabi B, United Kingdom; Hashimoto K, Japan
Received: April 9, 2022
Peer-review started: April 9, 2022
First decision: June 16, 2022
Revised: June 24, 2022
Accepted: August 24, 2022
Article in press: August 24, 2022
Published online: October 6, 2022

Abstract

BACKGROUND
Extranodal natural killer/T cell lymphoma, nasal type (ENKL) is a highly aggressive malignancy characterized by its association with Epstein-Barr virus (EBV) and extranodal involvement, which shows a poor clinical outcome. Although L-asparaginase-based chemotherapy has improved the response rates of relapsed/refractory (R/R) ENKL, relapse occurs in up to 50% of patients with disseminated disease.

CASE SUMMARY
Immune evasion has emerged as a critical pathway for survival in ENKL and may be effectuated via STAT3-driven upregulation of programmed cell death ligand 1 (PD-L1) or other molecular pathways. Anti-PD-1 is effective for R/R ENKL with EBV-driven upregulation of PD-L1 expression. Anti-PD-1 combined with decitabine showed positive preliminary results in a patient with R/R ENKL and resistance to anti-PD-1.

CONCLUSION
The treatment experience, in this case, demonstrated the potential ability of decitabine combined with PD-1 inhibitor to treat R/R ENKL, thus providing a new treatment strategy for this tumor.

Key Words: NK-T cell lymphoma; Refractory/relapsed; Anti-PD-1; Decitabine; Case report

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
**Core Tip:** Extranodal natural killer/T cell lymphoma nasal type is a highly aggressive malignancy characterized by its association with Epstein-Barr virus and extranodal involvement, which shows a poor clinical outcome. Now, we report a rare case of relapsed/refractory classic Hodgkin lymphoma with resistance to anti-PD-1 in which anti-PD-1 combined with decitabine showed positive preliminary results. Our findings support the potential benefit of anti-PD-1 combined with decitabine in this type of refractory T-cell lymphoma.

**INTRODUCTION**

Extranodal natural killer/T cell lymphoma (ENKL) is a rare T-cell lymphoma with a poor prognosis and poor response to conventional chemotherapy. ENKL is more prevalent in China than in Western countries[1,2]. It is a highly aggressive lymphoma with poor efficacy and prognosis by traditional treatments[3,4]. The treatment options for relapsed/refractory (R/R) ENKL are still limited, and improving the treatment is an urgent requirement. Some studies have shown that ENKL cells avoid immune surveillance and the consequent killing of ENKL, resulting in a poor outcome[5].

**CASE PRESENTATION**

**Chief complaints**

A 54-year-old male patient was admitted to our hospital with a diagnosis of ENKL for > 4 years.

**History of present illness**

About 4 years ago, the patient visited our hospital for recurrent gingival bleeding accompanied by night sweats and a recent weight loss of > 10 kg. Positron emission tomography/computed tomography (PET/CT) showed multiple lymphadenopathies in the bilateral neck and supraclavicular area (especially in the right neck), strip-shaped soft tissue density shadow in the right nasal cavity, and significantly increased fluorodeoxyglucose (FDG) metabolism (Figure 1). Biopsy of the right nasal septum mucosa was performed postoperatively, and the pathology showed ENKL. Immunohistochemistry showed CD3 +, CD4 +, CD56 +, granzyme B +, CD8 -, CD20 -, Pax5 -, and Ki-67 + (about 80%). Molecular in situ hybridization demonstrated positivity for EBER (Figure 2).

**History of past illness**

The patient had no history of past illness.

**Personal and family history**

No personal or family history was available.

**Physical examination**

There were multiple lymphadenectasis in the bilateral neck especially in the right neck. No palpable enlargement of the liver or spleen was noted.

**Laboratory examinations**

The liver function, renal function, routine blood tests, myocardial enzymes, and coagulation function were normal. Bone marrow puncture was not performed.

**Imaging examinations**

On March 3, 2018, PET/CT showed multiple lymphadenopathies in the bilateral neck and supraclavicular area (especially in the right neck), strip-shaped soft tissue density shadow in the right nasal cavity, and significantly increased FDG metabolism and a high standard uptake value (SUV) with a Deauville score of 7.6 (Figure 1).

On June 6, 2017, PET/CT showed that the original lesions in the right nasal cavity, bilateral neck, and supraclavicular area had subsided and become inactive compared to the scan on March 3, 2017. However, there was new large, curved wall thickening of the gastric body, multiple nodules of the...
Li LJ et al. Treatment of refractory/relapsed ENKL

Figure 1 Multiple lymphadenopathies in the bilateral neck and supraclavicular area (especially in the right neck), strip-shaped soft tissue density shadow in the right nasal cavity, and significantly increased fluorodeoxyglucose metabolism as revealed by standard uptake value (SUV) with a Deauville score of 7.6.

spleen, multiple lymphadenopathies around the stomach, mediastinum and left hilum, and increased FDG metabolism (Figure 3). 
On November 9, 2021, PET/CT showed that right mediastinal paratracheal, right main bronchial, and subcarinal lymph nodes and ileocecal small nodules subsided and became inactive, and the metabolism of left lower lobe nodules was decreased significantly (SUVmax decreased from 10.2 to 3.8) (Figure 4).

**FINAL DIAGNOSIS**

According to the above medical history, the final diagnosis was ENKL.

**TREATMENT**

After diagnosis, the patient was given SMILE regimen for two cycles (methotrexate 4.5 g d1, dexamethasone 40 mg d1–4, ifosfamide 2 g d2–4, etoposide 160 mg d2–4, L-asparaginase 3200 U d5) on March 10 and April 8, 2017, respectively. Since May 2, 95% planned target volume at 54 Gy/28 f was irradiated to the local lesion and irregular large-area fields on both sides of the neck. PET/CT on June 6, 2017 showed that the original lesions in the right nasal cavity, bilateral neck, and supraclavicular area have subsided and become inactive compared to the scan on March 3, 2017. However, there was new large, curved wall thickening of the gastric body, multiple nodules of the spleen, multiple lymphadenopathies around the stomach, mediastinum, and left hilum, and increased FDG metabolism (Figure 3). Gastroscopic pathological biopsy suggested ENKL. Then, DDGP regimen plus methotrexate (gemcitabine 1.63 g d1 and 8, methotrexate 3.20 g d1–4, dexamethasone 30 mg d1–4, L-asparaginase 3750 U d5) chemotherapy was administered for two cycles. On August 30, after SMILE regimen was repeated, stem cells were prepared for autologous stem cell transplantation, but the collection failed. On October 27, modified SMILE regimen (dexamethasone 32 mg d1–4, etoposide 100 mg d2–4, methotrexate 3.6 g d1, L-asparaginase 3750 U d5) chemotherapy was administered. Compared to June 6, 2017, the PET/CT on November 17 showed that the original lesions of the left lung, great curvature of the gastric body, perigastric, spleen, mediastinum, and left hilum had subsided and become inactive, but there were new lesions on the pancreatic head and right lung, with increased FDG metabolism. The patient revisited our hospital, and he was considered with refractory lymphoma. Thus, pembrolizumab 200 mg was administered every 21 d. The follow-up PET/CT after 6 mo showed complete remission of lymphoma. So, the maintenance treatment was continued for > 2 years. However, in July 2021, PET/CT
Li LJ et al. Treatment of refractory/relapsed ENKL

Figure 2 Molecular in situ hybridization demonstrated positivity for EBER. A: Tumor cells are large, nucleus pleomorphic or elongated, deeply stained, diffuse, and patchy (hematoxylin-eosin staining, × 400); B: EBER positivity (in situ hybridization, × 400); C: CD3 positivity (Envision two-step immunohistochemical staining, × 400); D: CD56-positivity (Envision two-step immunohistochemical staining, × 400); E: Granzyme B positivity (Envision two-step immunohistochemical staining, × 400); F: Ki-67 positive expression rate of 80%.

showed that the right mediastinal paratracheal, right main bronchial, and subcarinal lymph nodes (groups 4R, 10R, and 7) were further enlarged. New nodules were added in the lower lobe of the left lung, and small nodules were added in the ileocecal part; all had significantly increased FDG metabolism (Figure 4). However, no tumor cells were found in the alveolar lavage fluid and bronchoscopic biopsy. Combined with the medical history and clinical presentation, this patient was considered with relapsed ENKL, and AspaMetDex regimen chemotherapy (methotrexate 3 g d1, dexamethasone 40 mg d1–4, L-asparaginase 3400 U d5) combined with chidamide 30 mg orally twice a week was used. Repeat CT showed that the lesions in the lower lobe of the left lung increased in size after two cycles. As the disease progressed, we utilized the regimen of decitabine 25 mg d1–5, sintilimab 200 mg d6, and L-asparaginase 3750 U d10 for combined chemotherapy.

OUTCOME AND FOLLOW-UP

The above scheme was repeated after 4 wk. PET/CT on July 16, 2021 showed that after 8 wk, the right mediastinal paratracheal, right main bronchial, subcarinal lymph nodes, and small ileocecal nodules subsided and were inactive, and the left lower lobe nodules, and FDG metabolism decreased significantly (Figure 4). This patient is still undergoing regular chemotherapy every 4 wk: Decitabine 25 mg d1–5, sintilimab 200 mg d6, and L-asparaginase 3750 U d10. To the best of our knowledge, this is the first case of decitabine combined with anti-PD-1 applied to R/R ENKL.
DISCUSSION

As an inhibitory receptor, PD-1, expressed on the surface of activated T cells, is involved in immune tolerance and the prevention of tissue damage associated with chronic inflammation. Inflammatory cytokines have been found to induce programmed cell death ligand 1 (PD-L1) expression in many studies. In particular, the involvement of IFN-γ in immune checkpoint induction has been reported. When the expression of proinflammatory cytokines was high, it suggests the possibility that the expression of PD-L1 Therefore, it suggests the possibility that the expression of PD-L1[6].

PD-1 interacts with its ligands PD-L1 and PD-L2 to inhibit T cell receptor signal, downregulate T cell activation and proliferation, and weaken the T cell-mediated anti-tumor immune response[7,8]. Therefore, the PD-1 pathway is an immune checkpoint that suppresses anti-tumor immunity. Other studies have reported the efficacy of anti-PD-1 in R/R ENKL[5,9].

Exhausted T cells, including memory-like exhausted T cells that respond to PD-1 inhibitors, ultimately differentiate into terminal exhausted T cells. These T cells are resistant to anti-PD-1-induced rejuvenation but can still exhibit distinct epigenetic profiles[10-12]. Another study identified low-dose DNA demethylating agents that alter T-cell’s epigenetic status and enhance the anti-tumor activity of PD-1/PD-L1 blockade therapy in mouse models[13,14]. Reportedly, T cell phenotype and function and the expression of PD-1 are strongly regulated by epigenetic changes[15,16]. Patients with hematological malignancies treated with hypomethylating agents have demonstrated increased expression of PD-1 transcripts and proteins on the cell surface[17,18]. With the expanding application of immune checkpoint inhibitors in hematological malignancies, immunotherapies targeting the PD-1/PD-L1 axis combined with hypomethylating agents may counteract the upregulation of PD-1/PD-L1 checkpoints and improve the clinical outcomes[18]. While anti-PD-1 alone had modest effects, hypomethylating agents followed by anti-PD-1 therapy inhibited tumor growth and prolonged the survival of the pancreatic cancer mouse model[19]. Wang et al[20] found that decitabine combined with anti-PD-1 achieves curative effects in patients with R/R Hodgkin’s lymphoma resistant to anti-PD-1 and is a safe and feasible approach. A randomized phase II study of R/R Hodgkin’s lymphoma demonstrated that anti-PD-1 plus decitabine was well-tolerated and improved the clinical outcomes compared to anti-PD-1 alone with regard to the duration of response (DOR) and progression-free survival (PFS)[21]. The common treatment-related adverse events, such as a benign and reversible skin condition, reactive capillary endothelial proliferation, and leukocytopenia, but no treatment-related infections, were identified[21]. Although this protocol has achieved good preliminary results in Hodgkin’s lymphoma and other tumors, this is the first attempt to use this combination therapy in R/R ENKL. Our patient was resistant to pembrolizumab after continual treatment for 2 years but still achieved near-complete
remission by decitabine combined with sintilimab. Although the binding sites of the two antibodies are different, more over the Fc side of sintinib was modified to avoid direct phagocytosis of antibody molecules. These mechanisms maybe result in the different response between these two antibodies. But as far as the current research is concerned, sintilimab has similar anti-tumor effects to other anti-PD-1 [22]. No treatment-related adverse events were noted in our case.

L-asparaginase-based chemotherapy improves the response rate of R/R ENKL. However, no studies have yet reported that L-asparaginase has a synergistic effect with anti-PD-1 or demethylated drugs.

CONCLUSION
The experience of this case offers a new option for the treatment of R/R ENKL resistant to anti-PD-1 and other types of lymphomas. This case is only an empirical report of a single case, and the efficacy of decitabine combined with anti-PD-1 in R/R ENKL needs to be confirmed in more patients.
FOOTNOTES

Author contributions: Zhang JY designed the report and wrote the paper; Li LJ collected the patient’s clinical data; all authors have read and approved the final version of this manuscript.

Supported by the Medical Health Science and Technology Project of Zhejiang Province Health Commission, No. 2020376298.

Informed consent statement: Informed written consent was obtained from the patient for the publication of this report and any accompanying images.

Conflict-of-interest statement: The authors declare that they have no conflict of interest to disclose.

CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country/Territory of origin: China

ORCID number: Lin-Jie Li 0000-0003-2674-2996; Jun-Yu Zhang 0000-0002-1013-8172.

S-Editor: Chen YL
L-Editor: Wang TQ
P-Editor: Chen YL

REFERENCES

1. Tse E, Kwong YL. How I treat NK/T-cell lymphomas. Blood 2013; 121: 4997-5005 [PMID: 23652805 DOI: 10.1182/blood-2013-01-453233]

2. Lee J, Suh C, Park YH, Ko YH, Bang SM, Lee JH, Lee DH, Huh J, Oh SY, Kwon HC, Kim HJ, Lee SI, Kim JH, Park J, Oh SJ, Kim K, Jung C, Park K, Kim WS. Extramedul natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol 2006; 24: 612-618 [PMID: 16380410 DOI: 10.1200/JCO.2005.04.1384]

3. Kwong YL, Anderson BO, Advani R, Kim WS, Levine AM, Lim ST, Asian Oncology Summit. Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 2009; 10: 1093-1101 [PMID: 19880063 DOI: 10.1016/S1470-2045(09)70265-7]

4. Li X, Cui Y, Sun Z, Zhang L, Li L, Wang X, Wu J, Fu X, Ma W, Zhang X, Chang Y, Nan F, Li W, Su L, Wang J, Xue H, Zhang M. DDGP versus SMILE in Newly Diagnosed Advanced Natural Killer/T-Cell Lymphoma: A Randomized Controlled, Multicenter, Open-label Study in China. Clin Cancer Res 2016; 22: 5223-5228 [PMID: 27060152 DOI: 10.1186/1748-0336-16-1015]

5. Li X, Cheng Y, Zhang M, Yan J, Li L, Fu X, Zhang X, Chang Y, Sun Z, Yu H, Zhang L, Wang X, Wu J, Li Z, Nan F, Tian L, Li W, Young KH. Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma. J Hematol Oncol 2018; 11: 15 [PMID: 29386072 DOI: 10.1186/s13045-018-0559-7]

6. Hashimoto K, Nishimura S, Ito T, Akagi M. Characterization of PD-1/PD-L1 immune checkpoint expression in soft tissue sarcomas. Eur J Histochem 2021; 65 [PMID: 34218652 DOI: 10.4081/ejh.2021.3203]

7. Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, Iwai Y, Long AJ, Brown JA, Nunes R, Greenfield EA, Bourque K, Boussiotis VA, Carter LL, Carreno BM, Malenkovich N, Nishimura H, Okazaki T, Honjo T, Sharpe AH, Freeman GJ. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2006; 7: 1331-1337 [PMID: 17067066 DOI: 10.1038/ni1041]

8. Liu D, Wang S, Binderman W. Clinical applications of PD-L1 bioassays for cancer immunotherapy. J Hematol Oncol 2017; 10: 110 [PMID: 28514966 DOI: 10.1186/s13045-017-0479-y]

9. Kwong YL, Chan TSY, Tan D, Kim SJ, Poon LM, Mow B, Khong PL, Loong F, Au-Yeung R, Iqbal J, Phippis C, Tse E. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase. Ann Hematol 2017; 96: 2437-2442 [PMID: 28188133 DOI: 10.1007/s00277-016-256841]

10. Philip M, Fairechild L, Sun L, Horste EL, Camara S, Shakiba M, Scott AC, Viale A, Lauer P, Merghoub T, Hellmann MD, Wolchok JD, Leslie CS, Schietinger A. Chromatin states define tumour-specific T cell dysfunction and reprogramming. Nature 2017; 545: 452-456 [PMID: 28154453 DOI: 10.1038/nature22367]

11. Jansen CS, Prokhnevskia N, Master VA, Sanda MG, Carlisle JW, Bilen MA, Cardenas M, Wilkinson S, Lake R, Sowalsky AG, Valanparambili RM, Hudson WH, McGuire D, Melnick K, Khan AI, Kim K, Chang YM, Kim A, Filson CP, Allemozaffar M, Osunkoya AO, Mullane P, Ellis C, Akondy R, Im SJ, Kamphorst AO, Reyes A, Liu Y, Kissieck H. An intra-tumoral niche maintains and differentiates stem-like CD8 T cells. Nature 2019; 576: 465-470 [PMID: 31827286 DOI: 10.1038/s41586-019-1836-5]
https://www.wjgnet.com

12 Miller BC, Sen DR, Al Aboys R, Bi K, Virkud YY, LaFleur MW, Yates KB, Lako A, Felt K, Naik GS, Manos M, Gjini E, Kuchroo JR, Ishizuka JI, Collier JL, Griffin GK, Maliar S, Comstock DE, Weiss SA, Brown FD, Panda A, Zimmer MD, Manguso RT, Hodi FS, Rodig SJ, Sharpe AH, Haining WN. Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. *Nat Immunol* 2019; 20: 326-336 [PMID: 30778252 DOI: 10.1038/s41590-019-0312-6]

13 Pauken KE, Sammons MA, Odorizzi PM, Manne S, Godec J, Khan O, Drake AM, Chen Z, Sen DR, Kurachi M, Barnitz RA, Bartman C, Bengsch B, Huang AC, Schenkel JM, Vahedi G, Haining WN, Berger SL, Wherry EJ. Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. *Science* 2016; 354: 1160-1165 [PMID: 27789795 DOI: 10.1126/science.aaf2807]

14 Weintraub K. Take two: Combining immunotherapy with epigenetic drugs to tackle cancer. *Nat Med* 2016; 22: 8-10 [PMID: 26735398 DOI: 10.1038/nm0116-8]

15 Suarez-Álvarez B, Rodríguez RM, Schlangen K, Raneros AB, Márquez-Kisinousky L, Fernández AF, Diaz-Corte C, Aransay AM, López-Larrea C. Phenotypic characteristics of aged CD4+CD28null T lymphocytes are determined by changes in the whole-genome DNA methylation pattern. *Aging Cell* 2017; 16: 293-303 [PMID: 28026094 DOI: 10.1111/acel.12552]

16 Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. *Annu Rev Immunol* 2008; 26: 677-704 [PMID: 18173375 DOI: 10.1146/annurev.immunol.26.021607.090331]

17 Koubach C, Liu D, Everett G, Kerber RE. Extreme intracardiac coiling of a transvenous pacemaker: a case report. *Pacing Clin Electrophysiol* 1985; 8: 360-363 [PMID: 2582382 DOI: 10.1097/00019731-198505000-00011]

18 Yang H, Bueso-Ramos C, DíNardo C, Estecio MR, Davaniou M, Geng QR, Fang Z, Nguyen M, Pierce S, Wei Y, Parmar S, Cortes J, Kantarjian H, García-Manero G. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndrome is enhanced by treatment with hypomethylating agents. *Leukemia* 2014; 28: 1280-1288 [PMID: 24270737 DOI: 10.1038/leu.2013.355]

19 Gonda TA, Fang J, Salas M, Do C, Hsu E, Zhukovskaya A, Siegel A, Takahashi R, Lopez-Bujanda ZA, Drake CG, Manji GA, Wang TC, Olive KP, Tycko B. A DNA Hypomethylating Drug Alters the Tumor Microenvironment and Improves the Effectiveness of Immune Checkpoint Inhibitors in a Mouse Model of Pancreatic Cancer. *Cancer Res* 2020; 80: 4754-4767 [PMID: 32816859 DOI: 10.1158/0008-5472.CAN-20-0285]

20 Wang C, Liu Y, Dong L, Li X, Yang Q, Brock MV, Mei Q, Liu J, Chen M, Shi F, Liu M, Nie J, Han W. Efficacy of Decitabine plus Anti-PD-1 Camrelizumab in Patients with Hodgkin Lymphoma Who Progressed or Relapsed after PD-1 Blockade Monotherapy. *Clin Cancer Res* 2021; 27: 2782-2791 [PMID: 33674274 DOI: 10.1158/1078-0432.CCR-21-0133]

21 Liu Y, Wang C, Li X, Dong L, Yang Q, Chen M, Shi F, Brock M, Liu M, Mei Q, Liu J, Nie J, Han W. Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma. *J Immunother Cancer* 2021; 9 [PMID: 33820822 DOI: 10.1136/jitc-2021-002347]

22 Zhang L, Mai W, Jiang W, Geng Q. Sintilimab: A Promising Anti-Tumor PD-1 Antibody. *Front Oncol* 2020; 10: 594558 [PMID: 33324564 DOI: 10.3389/fonc.2020.594558]
